780 related articles for article (PubMed ID: 33571162)
1. Durable SARS-CoV-2 B cell immunity after mild or severe disease.
Ogega CO; Skinner NE; Blair PW; Park HS; Littlefield K; Ganesan A; Dhakal S; Ladiwala P; Antar AA; Ray SC; Betenbaugh MJ; Pekosz A; Klein SL; Manabe YC; Cox AL; Bailey JR
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571162
[TBL] [Abstract][Full Text] [Related]
2. Durable SARS-CoV-2 B cell immunity after mild or severe disease.
Ogega CO; Skinner NE; Blair PW; Park HS; Littlefield K; Ganesan A; Ladiwala P; Antar AA; Ray SC; Betenbaugh MJ; Pekosz A; Klein SL; Manabe YC; Cox AL; Bailey JR
medRxiv; 2020 Oct; ():. PubMed ID: 33140070
[TBL] [Abstract][Full Text] [Related]
3. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies.
Jeffery-Smith A; Burton AR; Lens S; Rees-Spear C; Davies J; Patel M; Gopal R; Muir L; Aiano F; Doores KJ; Chow JY; Ladhani SN; Zambon M; McCoy LE; Maini MK
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34843448
[TBL] [Abstract][Full Text] [Related]
5. Evolution of antibody immunity to SARS-CoV-2.
Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC
Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of RBD
Abayasingam A; Balachandran H; Agapiou D; Hammoud M; Rodrigo C; Keoshkerian E; Li H; Brasher NA; Christ D; Rouet R; Burnet D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Stella AO; Fichter C; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Tea F; Pilli D; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA;
Cell Rep Med; 2021 Apr; 2(4):100228. PubMed ID: 33748788
[TBL] [Abstract][Full Text] [Related]
7. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.
Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA;
Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
10. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease.
Reyes RA; Clarke K; Gonzales SJ; Cantwell AM; Garza R; Catano G; Tragus RE; Patterson TF; Bol S; Bunnik EM
PLoS One; 2021; 16(12):e0261656. PubMed ID: 34936684
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
14. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence.
Hartley GE; Edwards ESJ; Aui PM; Varese N; Stojanovic S; McMahon J; Peleg AY; Boo I; Drummer HE; Hogarth PM; O'Hehir RE; van Zelm MC
Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33443036
[TBL] [Abstract][Full Text] [Related]
15. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
[TBL] [Abstract][Full Text] [Related]
17. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
19. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
Aguilar-Bretones M; Westerhuis BM; Raadsen MP; de Bruin E; Chandler FD; Okba NM; Haagmans BL; Langerak T; Endeman H; van den Akker JP; Gommers DA; van Gorp EC; GeurtsvanKessel CH; de Vries RD; Fouchier RA; Rockx BH; Koopmans MP; van Nierop GP
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34499051
[TBL] [Abstract][Full Text] [Related]
20. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N
Front Immunol; 2021; 12():636768. PubMed ID: 33777028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
